Atopic dermatitis (AD) is the most common chronic skin inflammatory disease worldwide, affecting up to 25% of children and 10% of adults. 1 A subset of patients with AD are susceptible to disseminated skin viral infection, including herpes simplex virus (HSV), molluscum contagiosum, and vaccinia virus. 2, 3 The most common viral complication in patients with AD is eczema herpeticum (atopic dermatitis with a history of eczema herpeticum [ADEH1]), which is mainly caused by HSV-1. 2 Patients with ADEH1 are invaluable resources for mechanistic investigations of the interplay between host immune defense and HSV-1 in human subjects. Based on this perspective, the National Institute of Allergy and Infectious Diseases funded the Atopic Dermatitis Research Network to investigate ADEH1 with comprehensive mechanistic studies.
Previously, we reported a study comparing transcriptomes of PBMCs from patients with atopic dermatitis without a history of eczema herpeticum (ADEH2) versus patients with ADEH1. 4 This study found that ankyrin repeat domain 1 (ANKRD1) was one of the most downregulated genes in ADEH1. 4 ANKRD1, which is also known as c-193 and cardiac ankyrin repeat protein, is a pleiotropic protein containing 4 ankyrin repeat domains; a nuclear localization signal; a sequence rich in proline, glutamic acid, serine, and threonine; and multiple phosphorylation consensus sites. 5 ANKRD1 was discovered as a nuclear DNAbinding protein induced by inflammatory cytokines in human dermal vascular endothelial cells. 5 Subsequently, ANKRD1 was found to be expressed abundantly in cardiac myocytes and skeletal muscle tissues, where they localized to the I band of sarcomere through binding to titin and myopalladin. [6] [7] [8] ANKRD1 can also enter the nuclei of cardiac myocytes to regulate cardiomyogenesis as a transcriptional regulator. 9 Upregulation and gene mutations of ANKRD1 are associated with cardiomyopathy. [10] [11] [12] Additionally, induction of ANKRD1 has been found in patients with ovarian cancer, injured podocytes, cutaneous wounds, TGF-b-induced mouse mammary epithelial cells, hepatitis C-infected hepatocytes, and papilloma virus-infected keratinocytes. [13] [14] [15] [16] [17] [18] Although ANKRD1 has been studied extensively, its induction by HSV-1 in human immune cells and the biological significance of this response have not been investigated.
In the current study we first confirmed our previous RNA sequencing results using an increased number of subjects, demonstrating that ANKRD1 transcripts were significantly downregulated in HSV-1-stimulated PBMCs from patients with ADEH1 compared with PBMCs from patients with ADEH2. We then explored regulation of ANKRD1 expression in PBMCs, its cell source, and its biological function in host antiviral responses. The results of our study support a functional role for reduced ANKRD1 expression in ADEH1 pathogenesis.
METHODS

Human subjects
Subjects ranging in age from 6 to 65 years participated in the study. They included 21 control subjects without atopy (nonatopic [NA] subjects), 19 patients with ADEH2, and 20 patients with ADEH1. The groups were stratified based on age and sex. None of the patients with ADEH1 had acute HSV-1 infection. All human subjects were examined for serum HSV-1 IgG and HSV-2 IgG values. Demographic characteristics of the 60 subjects are shown in Table E1 in this article's Online Repository at www.jacionline.org. An additional 10 healthy adults were recruited to participate in the mechanistic investigation. The institutional review board at National Jewish Health approved the study, and all subjects provided written informed consent to participate.
Virus, pattern recognition receptor agonists, recombinant cytokines, neutralization antibodies, and plasmids HSV-1 virus stock (VR-733) was purchased from the ATCC (Manassas, Va). The pattern recognition receptor (PRR) agonists CpG (ODN2395); CL264 (catalog no. tlrl-c264e); LPS (catalog no. tlrl-b5lps); Pam3CSK4 (catalog no. tlrl-pms); poly(deoxyadenylic-deoxythymidylic) acid sodium salt (Poly dA:dT; catalog no. tlrl-patc); polyinosinic-polycytidylic acid, low molecular weight (PolyI:C-LMW; catalog no. tlrl-picwlv); polyI:C-Tolllike receptor (TLR) 3 agonist (catalog no. tlrl-picw); and SS40 (catalog no. tlrl-lrna40) were purchased from InvivoGen (San Diego, Calif). Recombinant human TNF-a (catalog no. 210-TA-020/CF), IL-1b (catalog no. 201-LB-005), IFN-g, IL-4, IL-22, GM-CSF, monoclonal mouse IgG 1 clone 11711 (catalog no. MAB002), human IL-1b/IL-1F2 antibody (MAB601), human TNFaR1/TNFRSF1A antibody (MAB625), and anti-human IFN-gR1 antibody (MAB6731) were bought from R&D Systems (Minneapolis, Minn). Recombinant human IFN-a (catalog no. 11101-1) and mouse anti-human IFN-a (catalog no. 21112-1) were purchased from PBL Biomedical Laboratories (Piscataway, NJ). Myc-DDK1-tagged RELA (RC220780), Myc-DDK1-tagged NFKB1 (RC208384), Myc-DDK1-tagged interferon regulatory factor (IRF) 7 (RC217934), Myc-DDK1-tagged ANKRD1 (RC205609) and Myc-DDK1-tagged STING were purchased from OriGene (Rockville, Md). Dr Hong-Bing Shu (Wuhan University, Wuhan, China) kindly provided pCMVflag-IRF3 and pCMV-flag-MyD88. PRK-neo-HA-ANKRD1 was generated in our laboratory by means of insertion of an encoding cDNA fragment in frame into the PRK-neo-HA vector (a kind gift from Dr Hong-Bing Shu).
PBMC isolation and purification of different cell types
Human PBMCs were isolated by using Ficoll-Hypaque density gradient centrifugation of heparinized venous blood from donors. PBMCs were subjected to sequential isolation of T cells, natural killer (NK) cells, and monocytes by using anti-CD3, anti-CD56, and anti-CD14 microbeads, according to the manufacturer's guidelines (Miltenyi Biotec, San Diego, Calif). Then the rest of the cells were further separated using a human B Cell Isolation Kit II purchased from Miltenyi Biotec to obtain B cells and dendritic cells. In some experiments we used antigen-presenting cells (APCs; ie, a mix of B cells, dendritic cells, and monocytes) isolated from PBMCs by depletion of T and NK cells.
Cell treatment
PBMCs and other cell types isolated from PBMCs were maintained in RPMI 1640 supplemented with 10% FBS, penicillin (50 IU/mL), and streptomycin (50 mg/mL). For 21 NA subjects, 20 patients with ADEH1, and 19 patients with ADEH2, one million PBMCs in 200 mL of culture media were stimulated with sham or HSV-1 at a multiplicity of infection (MOI) of 0.1 for 21 hours. For mechanistic studies, PBMCs and other types of cells were suspended in complete RPMI 1640 at 1 3 10 6 cells/mL, seeded in 96-well plates, and stimulated with HSV-1 at an MOI of 0, 0.01, and 0.1 and various PRR agonists and cytokines for 24 hours. For experiments with neutralizing antibodies, PBMCs were first incubated with antibody at 5 mg/mL for 2 hours and then exposed to medium or the TLR9 agonist CpG ODN 2395 at 50 or 200 mmol/L for an additional 24 hours. Cells were harvested at the end of treatment for RNA extraction and real-time PCR.
Small interfering RNA silencing experiment 
RNA extraction and real-time PCR analysis
Total RNA was extracted from cells by using RNeasy Mini Kits (Qiagen, Valencia, Calif), according to the manufacturer's guidelines. RNA was reverse transcribed into cDNA by using SuperScript III Reverse Transcriptase (Invitrogen). Real-time PCR was conducted in an ABI Prism 7000 sequence detector (Applied Biosystems, Foster City, Calif), as previously described. 19 Primers for ANKRD1 (Hs00923599_m1), IL29 (Hs00601677_g1), IFNB1 (Hs01077958_s1), HPRT1 (Hs02800695_m1), and 18S (Hs99999901_s1) were purchased from Applied Biosystems. Primer sequences for transcripts of HSV-1 were prepared, as previously described. 20 Quantities of all target genes in test samples were normalized to the corresponding HPRT1 and 18S levels.
Overexpression, co-immunoprecipitation, and Western blotting
We purchased 293FT cells from Invitrogen, and cells were maintained in Dulbecco modified Eagle medium with 4.5 g/L glucose, 10% FBS, and penicillin/streptomycin (50 U/mL/50 mg/mL; Life Technologies, Carlsbad, Calif). For overexpression experiments, cells were seeded in 24-well dishes at 1 3 10 5 cells/well on the day before transfection. The following day, pCMV6-AN-HA, HA-ANKDR1, and IRF3-Flag at 0.4 mg/well or indicated amounts were transfected into cells. Cells were harvested after 24 hours of transfection or after stimulation with Poly I:C-LMW for an additional 8 hours. Western blotting and qRT-PCR assays were performed with these samples. For coimmunoprecipitation experiments, cells were seeded in 100-mm-diameter Petri dishes at 80% to 90% of confluence the day before transfection.
The following day, plasmids of Flag-tagged or Myc-DDK1-tagged IRF3, IRF7, NFKB1, RELA, STING, and MyD88 (10 mg of each) were cotransfected with 10 mg of hemagglutinin (HA)-tagged ANKRD1 by using Lipofectamine 2000, according to the manufacturer's guidelines (Invitrogen). After overnight incubation, cells were harvested and lysed in 1 mL of protein lysis buffer (20 mmol/L Tris-HCl [pH 7.4], 150 mmol/L NaCl, 1 mmol/L EDTA, and 1% Triton-X100) supplemented with protease inhibitor (Sigma-Aldrich, St Louis, Mo). Protein lysates were incubated with 0.5 mg of anti-HA antibody and 30 mL of protein A/G plus agarose (Santa Cruz Biotechnology, Dallas, Tex) in 1.5-mL Eppendorf tubes and rotated at 48C for 1 hour. Beads were then washed 3 times by using protein lysis buffer with 0.5 mol/L NaCl. After washing, 30 mL of the 23 Laemmli sample buffer (Bio-Rad Laboratories, Hercules, Calif) was added into the beads and then boiled for 5 minutes. Supernatants from each sample were then subjected to Western blotting for detection of either Flag/DDK1-tagged protein or HA-tagged protein. Both anti-Flag antibody and anti-HA antibody were purchased from Sigma-Aldrich. A standard Western blot protocol was used.
Statistical analysis
Comparisons between NA subjects, patients with ADEH2, and patients with ADEH1 in ANKRD1 gene expression were analyzed by using a general linear mixed model, adjusting for sex. Log transformation was performed on normalized gene expression values, and least-squares means were used for group comparisons between NA subjects versus patients with ADEH2, NA subjects versus patients with ADEH1, and patients with ADEH2 versus patients with ADEH1. No adjustments for multiple comparisons were made. SAS software (version 9.4; SAS Institute, Cary, NC) was used for all analyses. Comparisons of expression levels were performed by using ANOVA techniques and independent-sample t tests, as appropriate. Differences were considered significant at a P value of less than .05.
RESULTS
Induction of ANKRD1 by HSV-1 in PBMCs from patients with ADEH1 is decreased
In a previous publication using a small number of patients and RNA sequencing, we reported that levels of RNA transcripts of ANKRD1 in PBMCs induced by HSV-1 infection were significantly lower in patients with ADEH1 (n 5 5) versus patients with ADEH2 (n 5 6). 4 To validate this observation, we investigated ANKRD1 expression in the presence and absence of HSV-1 stimulation in 21 NA subjects, 19 patients with ADEH2, and 20 patients with ADEH1. As shown in Fig 1, ANKRD1 transcripts were expressed at either extremely low levels or were undetectable in PBMCs without HSV-1 exposure. On HSV-1 stimulation, ANKRD1 transcription was induced significantly in PBMCs in all 3 groups; however, levels in PBMCs from patients with ADEH1 was significantly lower than that in HSV-1-stimulated PBMCs from patients with ADEH2 (P < .001).
To exclude the confounding factor of previous HSV-1 exposure that might affect responses of PBMCs to HSV-1, we further analyzed the data based on HSV-1 IgG serologic positivity. Ten NA subjects, 8 patients with ADEH2, and 20 patients with ADEH1 were HSV-1 IgG positive. Among them, 1 NA subject, 2 patients with ADEH2, and 1 patient with ADEH1 also were HSV-2 IgG positive (see Table E1 ). Two NA subjects who were HSV-2 IgG positive alone were excluded in the analyses. As shown in Fig 1, B, ANKRD1 transcription levels in the ADEH1 group (0.041 6 0.006, n 5 20) were still significantly lower than those in the HSV-1 IgG-positive ADEH2 group (0.169 6 0.087, n 5 8; P 5 .028), whereas there were no significant differences between HSV-1 IgG-positive subjects and HSV-1 IgG-negative subjects for both the NA (P 5 .14) and ADEH2 (P 5 .15) groups.
ANKRD1 transcription is significantly induced by PRR agonists and cytokines
Because we found that ANKRD1 transcription could be induced in PBMCs by HSV-1 virus and host innate immune cells recognize invading viruses through various PRRs, 21 we determined whether Pam3CSK4 (TLR2 agonist), CpG (TLR9 agonist), Poly dA:dT (cytoplasmic DNA sensor agonist), LPS (TLR4 agonist), CL264 (TLR7 agonist), Poly I:C-LMW (cytoplasmic RNA sensor), Poly I:C-TLR3 and SS40 (TLR8 agonist) could induce ANKRD1 gene expression. As shown in Fig 2, A, all these agonists upregulated ANKRD1 gene expression in PBMCs.
To determine whether upregulation of ANKRD1 was a direct effect of PRR signal activation or a secondary effect mediated by cytokine production after PRR activation, we tested a panel of human recombinant cytokines and found FIG 2. Induction of ANKRD1 by PRR agonists is the secondary effect of cytokines. A, PBMCs from 5 healthy subjects were treated with HSV-1 and various PRR agonists for 21 hours. ANKRD1 mRNA expression levels were evaluated by using qRT-PCR. *P < .05 and **P < .01. B, PBMCs from healthy subjects (n 5 3) were treated with various cytokines at the indicated concentrations. ANKRD1 mRNA expression levels were evaluated by using qRT-PCR. Data are shown as means 6 SEs. C, PBMCs from healthy subjects (n 5 3) were pretreated with 5 mg/mL of the indicated neutralizing antibodies for 2 hours, and cells were then treated with indicated doses of ODN2395 for an additional 21 hours. ANKRD1 mRNA expression levels were evaluated by using qRT-PCR. Data are shown as means 6 SEs.
that ANKRD1 gene expression could be upregulated in human PBMCs by IFN-a, IFN-g, TNF-a, and IL-1b but not IL-29, IL-4, IL-22, and GM-CSF (Fig 2, B) . We then used neutralizing antibodies to block the activity of IFN-a, IFN-g, TNFa, and IL-1b. We found that PBMCs pretreated with anti-IFN-a, anti-IFN-gR1, anti-IL-1b, and anti-TNFR1, but not the control IgG, had reduced ANKRD1 gene expression on CpG stimulation, demonstrating that CpG-induced ANKRD1 expression is a secondary response of CpG-induced cytokine production (Fig 2, C) . Knockdown of ANKRD1 enhances HSV-1 viral loads and reduces type I and type III interferon production in APCs. Primary APCs from healthy subjects (n 5 3) were isolated by means of depletion of T and NK cells. Cells were then transfected with scrambled siRNA duplexes and ANKRD1 siRNA duplexes. After 24 hours of incubation, HSV-1 at indicated doses was added to cultures for an additional 24 hours of incubation. Cells were then harvested for RNA extraction and qRT-PCR. A-D, ANKRD1 (Fig 4, A) , HSV1 (Fig 4, B) , IFNB1 (Fig 4, C) , and IL29 (Fig 4, D) were evaluated by using qRT-PCR. E, Primary dendritic cells from healthy subjects (n 5 3) were isolated and transfected with siRNA duplexes for 24 hours. Cells were then stimulated with ODN 2395 for an additional 24 hours. ANKRD1, IFNB1, and IL29 were evaluated by using qRT-PCR. Data are represented as means 6 SEs. Data are representative of 3 independent experiments.
ANKRD1 transcription is induced predominantly in primary human APCs by HSV-1
To determine which cell types in PBMCs express ANKRD1, we purified T cells, NK cells, B cells, monocytes, and dendritic cells and stimulated these cells with HSV-1 at 0, 0.01, and 0.1 MOI for 24 hours. ANKRD1 transcription levels were significantly induced in APCs (ie, B cells, monocytes, and dendritic cells) but not in T and NK cells (Fig 3, A) . Additionally, we detected increased protein expression of ANKRD1 in HSV-1-stimulated mixed APCs but could not detect ANKRD1 protein in both sham-and HSV-1-treated T and NK cells, as well as sham-treated APCs (Fig 3, B) . Induction of ANKRD1 mRNA by HSV-1 was only found in primary APCs but not in EBV-transformed B-cell lines or the U937 and THP-1 human monocyte cell lines (data not shown). Additionally, ANKRD1 was not induced by IFN-a, IFN-g, TNF-a, and IL-1b in these cell lines (data not shown). These data suggest that induction of ANKRD1 expression by HSV-1 and cytokines can occur specifically in primary APCs but not transformed cells or monocyte cell lines.
Gene knockdown of ANKRD1 impairs innate immune responses against HSV-1
Because HSV-1 upregulates predominantly ANKRD1 transcription in APCs, we hypothesized that it might be involved in antiviral innate immune responses. To test this hypothesis, we silenced the expression of ANKRD1 in human APCs and then stimulated cells with various doses of HSV-1. We then evaluated HSV-1 viral load, as well as HSV-1-induced type I and type III interferon levels, because type I (IFN-a/IFN-b) and type III interferons (IL-29/IL-28A) are the most important cytokines that protect host cells from HSV infection. [22] [23] [24] As shown in Fig 4 , silencing ANKRD1 led to significantly increased HSV-1 viral loads and decreased IL29 and IFNB1 mRNA expression compared with those seen in cells transfected with scrambled siRNA. We also found that silencing ANKRD1 transcription in primary dendritic cells leads to decreased IL29 and IFNB1 mRNA levels in response to CpG stimulation (Fig 4, E) . These results suggest that ANKRD1 is involved in antiviral innate immune signaling pathways, specifically signaling pathways leading to the production of type I and type III interferons.
ANKRD1 forms protein complexes with IRF3
Because the current study found that ANKRD1 expression can be induced by multiple PRR agonists and cytokines (Fig 2, A and  B) , we hypothesized that it might interact with some master regulators in PRR signaling transduction pathways. PRRs mediate their signaling through 3 major master regulators: IRF3, IRF7, and nuclear factor kB (NF-kB).
21,25 Therefore we examined whether ANKRD1 could form protein complexes with IRF3 and IRF7, as well as the 2 subunits of NF-kB: RELA and NFkB1. Two cytoplasmic adaptor proteins, STING-Flag and MyD88-Flag, were used as controls. As shown in Fig 5, IRF3 -DDK1, IRF7-DDK1, and NF-kB1-DDK1 were all pulled down by HA-ANKRD1 but not RELA-DDK1, STING-Flag, and MyD88-Flag. Additionally, IRF3-DDK1 and NFkB1-DDK1 had quantitatively more protein pulled down by HA-ANKRD1, although the amount of protein in the lysates was similar, suggesting that ANKRD1 might complex preferentially with IRF3 and NF-kB1 rather than IRF7. Our data support the previous report that ANKRD1 interacts with NF-kB1. 26 Additionally, we identified IRF3 and IRF7 as new binding partners for ANKRD1.
Overexpression of ANKRD1 enhances the IRF3 signaling pathway
Because ANKRD1 forms protein complexes with IRF3 and IRF7 and knockdown of ANKRD1 impairs innate immune responses against HSV-1 in APCs, we then investigated whether overexpression of ANKRD1 affects IFNB1 and IL29 induction. HA-ANKRD1 and pCMV6-AN-HA empty vectors were transfected transiently into 293FT cells and then stimulated with different concentrations of poly I:C-LMW, an agonist that activates the IRF3/IRF7 signaling pathway. As shown in Fig 6, A, both IFNB1 and IL29 were significantly enhanced in HA-ANKRD1-overexpressed cells compared with control cells transfected with pCMV6-AN-HA empty vector on poly I:C-LMW stimulation. We also transfected IRF3-Flag with or without cotransfection of HA-ANKRD1. We found that HA-ANKRD1 by itself did not induce IL-29; however, it did enhance IRF3-Flag-induced IL-29 in 293T cells (Fig 6, B) . These data provide further support that ANKRD1 plays a role in the IRF3 signaling pathway by enhancing induction of type I and type III interferons.
DISCUSSION
ADEH1 is a devastating complication of AD because it can be complicated by keratoconjunctivitis, viremia, meningitis, and encephalitis. 27 It has been postulated that the increased propensity of patients with AD to eczema herpeticum might be caused by reduced antimicrobial peptides and skin barrier proteins because of the influence of T H 2 cytokines. 28, 29 Additionally, decreased interferon responses have been reported to play a role in ADEH1 etiology. 4, 30 To date, the molecular biomarkers that distinguish ADEH1 from ADEH2 have not been identified. In the current study we identified that ANKRD1 was significantly decreased in PBMCs from patients with ADEH1 on HSV-1 stimulation compared with PBMCs from patients with ADEH2 (Fig 1) . Forty-two percent of patients with ADEH2 in our study (n 5 8) were serologically HSV-1 IgG positive, suggesting that they have had prior HSV-1 exposure. After we stratified subjects based on their HSV-1 IgG positivity, ANKRD1 induction was still significantly greater in patients with ADEH2 compared with patients with ADEH1 (Fig 1, B) . This result demonstrates that reduced ANKRD1 levels in PBMCs from patients with ADEH1 in comparison with patients with ADEH2 are not caused by differences in HSV-1 exposure history, supporting the concept that there are fundamental differences between patients with ADEH2 and patients with ADEH1.
The current study is the first to demonstrate that ANKRD1 is induced by HSV-1 virus, PRRs, and interferons in human PBMCs. Although previous studies reported that ANKRD1 could be induced by hepatitis C virus (HCV) in hepatocytes, by human papillomavirus (HPV) in keratinocytes, and by IL-1a, TNF-a, and LPS in endothelial cells, 5, 16, 17 the current study examined a more comprehensive spectrum of stimuli on ANKRD1 induction in human PBMCs compared with prior studies. We further demonstrate that the induction of ANKRD1 by PRRs might be a secondary effect of PRR-induced cytokine production because the neutralizing antibodies of cytokines can reduce ANKRD1 induction by CpG (Fig 2, C) .
ANKRD1 has been studied extensively in cardiac myocyte biology and pathology, where it is expressed at the highest level. Although ANKRD1 knockout mice are born normal, 31 upregulation of ANKRD1 has been found in cardiac tissues caused by cardiac overload, hypertension, and heart failure. [32] [33] [34] Induction of ANKRD1 has also been reported in various physiologic and pathologic conditions in different tissues and cells. Because ANKRD1 is significantly upregulated in skin wounds, it has been suggested to play a role in angiogenesis and tissue remodeling through regulation of MMP13 gene expression in wound repair. 15, 35, 36 ANKRD1 upregulation has also been found in ovarian cancer cells. Inhibition of ANKRD1 in ovarian cancer cells promotes cisplatin-induced apoptosis. 37 Additionally, Matsuura et al 14 reported that ANKRD1 was upregulated in renal podocytes by LPSinduced injury, and its upregulation was associated with proteinuria in patients with lupus nephritis.
In the case of viral infections, Kaczkowski et al 17 found ANKRD1 was upregulated by HPV11, HPV16, and HPV45 in the HaCat keratinocyte cell line, but they did not investigate the biological significance of this response. Than et al 16 found that ANKRD1 was induced significantly by HCV in hepatocytes. Their study suggested that ANKRD1 might been involved in facilitating HCVentry. Although previous studies could not definitively address the biological function of ANKRD1 protein, these studies revealed a common phenomenon that ANKRD1 was upregulated by various different types of stress and insults, suggesting that ANKRD1 acts as a danger sensor. In the current study we found ANKRD1 was significantly induced in human primary APCs by HSV-1, demonstrating that upregulation of ANKRD1 is a response to HSV-1 infection. Thus our current study provides an additional example to support the notion that ANKRD1 is a danger sensor.
In the context of cardiomyogenesis, ANKRD1 has been found to interact with several transcription factors, including Y-box transcription factor 1, androgen receptor, the p50 subunit of NFkB, and p53. 6, 26, 38, 39 Functionally, ANKRD1 works as a repressor to suppress the transcriptional activity of Y-box transcription factor 1, androgen receptor, and p50, whereas it works as a coactivator to p53. Our current study demonstrates that ANKRD1 mRNA expression is at either very low or undetectable levels in PBMCs in different subjects when they are unstimulated. Its expression is significantly induced by the stimulation of PRR-induced cytokines, including interferons (Fig 2) . This suggests that upregulation of ANKRD1 in PBMCs is a response to activation of viral recognition pathways, leading us to hypothesize that it might function in virus-induced host cell innate immunity. HSV-1 viruses are known to activate innate immune cells to produce type I/type III interferons through multiple PRR signaling pathways. 16, [40] [41] [42] [43] [44] The interferons then prepare host cells to enter an ''antiviral state'' by producing large amounts of antiviral proteins to inhibit the replication of invading viruses. Viral recognition pathways of TLR3, retinoic acid-inducible protein 1/melanoma differentiation-associated gene 5, and cyclic GMP-AMP synthase/stimulator of interferon genes signaling pathways all use the transcription factor IRF3 to transduce the signaling cascade to production of type I and type III interferons.
In some cases the transcription factor IRF7 cooperates with IRF3 to promote interferon production. 25 Therefore we investigated whether IRF3 and IRF7 were the binding partners of ANKRD1. As expected, ANKRD1 interacts with IRF3 and IRF7, but it binds mainly with IRF3 (Fig 5) . Functionally, we found that silencing ANKRD1 led to enhanced HSV-1 viral load and reduced production of the antiviral cytokines IFNB1 and IL29, in response to HSV-1 stimulation (Fig 4, A-D) . When ANKRD1 is overexpressed, it enhances poly I:C-induced IFNB1 and IL29 transcription; coexpression of ANKRD1 and IRF3 also enhances IRF3-induced IL29 (Fig 6) . These data suggest that ANKRD1 works in a positive feedback loop to regulate viral recognition pathways (ie, after upregulation by PRRs) and that it promotes optimal type I/III interferon production by working as a coactivator of IRF3 in viral recognition pathways.
We also detected interaction of ANKRD1 and NF-kB1 (p50). However, we found silencing ANKRD1 led to reduced interferon transcription by the TLR9 agonist CpG stimulation (Fig 4, E) . TLR9-activated interferon responses are mainly transduced by NF-kB. 21 Therefore our results suggest that ANKRD1 acts as a coactivator to NF-kB in APCs. This contradicts a previous study by Liu et al, 26 who found ANKRD1 inhibited TNF-a-induced NF-kB activity in myoblasts. This discrepancy can be explained by cell type-specific responses, although further work is needed to sort out these differences.
In summary, our study has identified ANKRD1 as a novel biomarker that is differentially expressed between patients with ADEH1 and patients with ADEH2. We demonstrate that it interacts with IRF3 and IRF7 and enhances IRF3-mediated signaling pathways. These findings suggest a novel antiviral pathway that is subverted in patients with AD prone to eczema herpeticum. 
